## Michael A Webster-Clark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6262021/publications.pdf

Version: 2024-02-01

1039880 1058333 19 229 9 14 citations g-index h-index papers 19 19 19 380 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in Medicine, 2021, 40, 1718-1735.	0.8	50
2	Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointestinal Endoscopy, 2019, 90, 360-369.	0.5	35
3	Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population. American Journal of Epidemiology, 2018, 187, 817-827.	1.6	23
4	Low agreement between modified-Schwartz and CKD-EPI eGFR in young adults: a retrospective longitudinal cohort study. BMC Nephrology, 2018, 19, 194.	0.8	16
5	Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population. American Journal of Epidemiology, 2019, 188, 426-437.	1.6	16
6	Target Validity: Bringing Treatment of External Validity in Line with Internal Validity. Current Epidemiology Reports, 2020, 7, 117-124.	1.1	15
7	Diagnostic Assessment of Assumptions for External Validity. Epidemiology, 2019, 30, 103-111.	1.2	12
8	Initiator Types and the Causal Question of the Prevalent New-User Design: A Simulation Study. American Journal of Epidemiology, 2021, 190, 1341-1348.	1.6	11
9	Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation. Epidemiology, 2020, 31, 605-613.	1.2	9
10	Translating claimsâ€based CHA <sub>2</sub> DS <sub>2</sub> â€VaSc and HASâ€BLED to ICDâ€10 M: Impacts mapping strategies. Pharmacoepidemiology and Drug Safety, 2020, 29, 409-418.	s of 0.9	9
11	Single-arm Trials With External Comparators and Confounder Misclassification. Medical Care, 2020, 58, 1116-1121.	1.1	9
12	Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International Journal of Cancer, 2021, 149, 394-402.	2.3	6
13	Realâ€world onâ€treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. Pharmacoepidemiology and Drug Safety, 2020, 29, 832-841.	0.9	4
14	Ways <scp>COVID</scp> â€19 may impact unrelated pharmacoepidemiologic research using routinely collected data. Pharmacoepidemiology and Drug Safety, 2021, 30, 400-401.	0.9	4
15	Effectiveness of adjuvant <scp>FOLFOX</scp> vs <scp>5FU</scp> / <scp>LV</scp> in adults over age 65 with stage <scp>II</scp> and <scp>III</scp> colon cancer using a novel hybrid approach. Pharmacoepidemiology and Drug Safety, 2020, 29, 1579-1587.	0.9	3
16	How subgroup analyses can miss the trees for the forest plots: AÂsimulation study. Journal of Clinical Epidemiology, 2020, 126, 65-70.	2.4	3
17	Alternative analytic and matching approaches for the prevalent newâ€user design: A simulation study. Pharmacoepidemiology and Drug Safety, 2022, 31, 796-803.	0.9	3
18	Validation of a 5‥ear Mortality Prediction Model among U.S. Medicare Beneficiaries. Journal of the American Geriatrics Society, 2020, 68, 2898-2902.	1.3	1

#	ŧ	Article	IF	CITATIONS
19	9	Assessing clinical trial effects on outcomes among pediatric and adolescent and young adult (AYA) patients with cancer. Cancer, 2021, 127, 648-649.	2.0	0